The research team, led by Alberto Fernández and Javier García-Alba of the Complutense University of Madrid, followed 57 adults with Down syndrome over a 24-month period. At the outset, participants were classified into three clinical groups based on their status along the Alzheimer’s disease continuum: 25 individuals were asymptomatic, 16 were in a prodromal stage, and 16 had already developed dementia. Each participant underwent clinical, neuropsychological, and biomarker assessments at baseline and again two years later, allowing the investigators to track how plasma levels of two key proteins changed over time and how those changes related to cognitive function.

The two biomarkers at the heart of the study were plasma neurofilament light chain, commonly abbreviated as NfL, and phosphorylated tau 217, or p-tau217. Neurofilament light is a structural protein released into the bloodstream when neurons are damaged, making it a general indicator of neurodegeneration. Phosphorylated tau 217, by contrast, is a form of the tau protein modified by the addition of phosphate groups, and it has emerged in recent years as one of the most specific blood markers of Alzheimer’s pathology, closely tracking the amyloid and tau deposits that define the disease in the brain.

The longitudinal design revealed a striking pattern: biomarker levels rose significantly over the two-year window only in the groups with pathological clinical status, that is, those classified as prodromal or demented. The steepest increases occurred in the dementia group, consistent with the idea that plasma markers of Alzheimer’s disease accelerate as the condition advances. Crucially, the asymptomatic group showed no comparable rise, suggesting that these blood measures remain relatively stable until the disease process has begun to manifest clinically.

Perhaps the most consequential finding concerned the predictive power of cognition. Among the neuropsychological measures collected at baseline, performance on the New Serial Learning Immediate test, or NSL-I, stood out as the strongest predictor of subsequent biomarker evolution. This test assesses episodic memory, the ability to encode and immediately recall new information, which is typically among the first cognitive domains affected by Alzheimer’s disease. The relationship was quantified precisely: each one-point increase in baseline NSL-I score was associated with a reduction of 0.035 units in the longitudinal increase of p-tau217 and a reduction of 0.463 units in the increase of NfL. In other words, better immediate memory performance at the start of the study foreshadowed slower accumulation of both Alzheimer-specific tau pathology and general neuronal injury over the following two years.

The clinical implications of this dose-response relationship are considerable. Because the NSL-I is a brief, low-cost assessment that can be administered in routine clinical settings, it could serve as an accessible screening tool to flag individuals with Down syndrome who are likely to experience rapid biomarker progression. This matters because diagnostic evaluation in this population has long been hampered by the absence of cognitive assessment instruments that are both sensitive to change and appropriately normed for people with intellectual disability. The study’s authors argue that episodic memory performance deserves a central place in monitoring protocols, not merely as a symptom to be catalogued but as an active predictor of the underlying biological trajectory.

Even more striking was the role of baseline p-tau217 in predicting clinical conversion. When the researchers examined which baseline measurements anticipated whether a participant would progress to a more advanced clinical stage during the follow-up period, only p-tau217 emerged as a significant predictor. Individuals whose baseline p-tau217 values were one unit above the sample median showed a 3.56-fold increased risk of clinical progression. This finding reinforces the growing consensus, reflected in recent diagnostic criteria from the Alzheimer’s Association and the International Working Group, that phosphorylated tau measured in plasma is not merely a correlate of disease but a genuine prognostic marker capable of identifying who will deteriorate before symptoms worsen.

The study builds on a rapidly expanding literature on blood-based biomarkers in Down syndrome. Because chromosome 21 carries the gene for amyloid precursor protein, people with Down syndrome have three copies of a key molecular ingredient of amyloid plaques, and virtually all of them develop the neuropathological hallmarks of Alzheimer’s disease by middle age. Previous cross-sectional work, including large studies published in The Lancet and Lancet Neurology, established that plasma p-tau217 and other markers can distinguish symptomatic from asymptomatic individuals with Down syndrome. What the new study adds is the temporal dimension: it demonstrates that these markers change measurably over just two years, that the rate of change depends on clinical status, and that both the rate of change and the risk of conversion can be anticipated from baseline measurements.

For clinicians and families, the practical message is twofold. First, a simple memory test can help identify which adults with Down syndrome are on a fast biological track, enabling closer monitoring and earlier access to care planning. Second, elevated plasma p-tau217 should be treated as a warning sign of impending clinical decline, warranting intensified follow-up. The authors explicitly frame their results as supporting the development of screening strategies to identify individuals at high risk of rapid cognitive decline and to inform the design of future therapeutic trials, where accurate stratification of participants is essential for detecting treatment effects.

There are, of course, limits to what a study of 57 participants followed for two years can establish, and the researchers note that larger and longer cohorts will be needed to confirm the findings and refine the predictive models. The datasets analyzed in the study are available from the corresponding author upon reasonable request under a data transfer agreement, and the work was supported by public funding from the Spanish Ministry of Science and Innovation. Still, the convergence of a brief cognitive measure and a specific blood protein into a coherent prognostic framework represents a meaningful step toward personalized risk assessment in Down syndrome, a population that has historically been excluded from the advances transforming Alzheimer’s care in the general population. As blood-based diagnostics move from research laboratories into routine practice, studies like this one help ensure that people with Down syndrome are not left behind.

Subject of Research: Longitudinal plasma biomarker and cognitive predictors of Alzheimer's disease progression in Down syndrome

Article Title: The link between plasma and cognitive markers for Alzheimer’s disease in Down syndrome: a longitudinal study

Article References: The link between plasma and cognitive markers for Alzheimer’s disease in Down syndrome: a longitudinal study. (n.d.). https://doi.org/10.1007/s00415-026-14165-6

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14165-6

Keywords: Down syndrome, Alzheimer's disease, p-tau217, neurofilament light, plasma biomarkers, episodic memory, longitudinal study, clinical conversion, dementia, neuropsychological testing, biomarker progression, Journal of Neurology